fashion -WSS

fashion

author：fashion 2025-10-02 22:27:33 - browse：9

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Coloradans with cystic fibrosis could lose access to Trikafta

knowledge

WSS

Why psychiatrists like me stop taking insurance

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

UCB departs biotech trade group BIO

The health care issue Democrats can’t solve: hospital reform

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Antibiotic resistance and the global rise in human conflict

knowledge

fashion

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Key Senate panel to consider PBM, drug pricing reform package

Apple is now the first public company to be valued at $3 trillion

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Moonlake's readout produced a cash windfall. Risks remain

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

hotspot

Goldman Sachs launches $650M fund for life science investments

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Sarepta Duchenne therapy fails to meet primary endpoint in trial

AdventHealth escalates lawsuit against insurance vendor Multiplan

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Lung cancer screening guidelines updated for cigarette smokers

focus

knowledge

explore

entertainment